Overexpression of ubiquitin specific proteases 44 promotes the malignancy of glioma by stabilizing tumor-promoter securin
Metrics: PDF 1209 views | HTML 1892 views | ?
Yongxiang Zou1,*, Guanzhong Qiu2,*, Lei Jiang1,*, Zheng Cai1, Wei Sun1, Hongkang Hu1, Chengyin Lu1, Weilin Jin3 and Guohan Hu1
1Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, PR China
2Department of Neurosurgery, General Hospital of Jinan Military Command, Jinan, PR China
3Institute of Nano Biomedicine and Engineering, Department of Instrument Science and Engineering, Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai, PR China
*These authors have contributed equally to this work
Guohan Hu, email: email@example.com
Weilin Jin, email: firstname.lastname@example.org
Keywords: glioma, USP44, securin, cell cycle
Received: December 21, 2016 Accepted: February 28, 2017 Published: March 22, 2017
Ubiquitin specific peptidase 44 (USP44) has been identified as an important component of spindle assemble checkpoint (SAC) to prevent the formation of aneuploidy. However, recent study raised a controversy about the effect of USP44 in tumor. Here, we first confirmed the intranuclear localization of USP44 by testing several specific antibodies to recognize endogenous USP44. Then, data from IHC and qRT-PCR assay indicated that the high expression of USP44 existed in high-grade glioma tissues and signified a poor prognosis. Knockdown of USP44 inhibited proliferation, migration and invasion, induced apoptosis, and arrested cell cycle in G2/M phase in the established glioma cell lines. Down-regulation of oncoprotein securin was detected in USP44 deficient cells, and the interaction of endogenous USP44 and securin was confirmed by immunoprecipitation in U251MG cells, which indicated that securin was a substrate of USP44, and might be stabilized by USP44. In vivo, knockdown of USP44 inhibited the tumorigenicity of U87MG cells significantly. Consequently, our findings suggested that overexpression of USP44 could enhance the malignancy of glioma via securin. USP44 might serve as a predictive biomarker, and the USP44-securin pathway might provide a new therapeutic strategy for the treatment of glioma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.